Navigation Links
Institutional Review Board Approval Obtained for Study of Kibow(R) Biotics in Dialysis Patients with End-stage Chronic Kidney Disease
Date:3/10/2011

PHILADELPHIA, March 10, 2011 /PRNewswire/ -- On the occasion of World Kidney Day, Kibow Biotech, Inc. is pleased to announce its renewed commitment, hope and support for the worldwide maintenance of healthy kidney function among all those people with kidney problems.

In addition, Kibow Biotech, Inc. would also like to announce that it has received Institutional Review Board (IRB) approvals for conducting human clinical trials with its patented, proprietary and probiotic dietary supplement product – Kibow® Biotics. These human clinical trials will soon be initiated on dialysis patients at Thomas Jefferson University in Philadelphia, PA and the State University of New York (Downstate Medical Center & King's County Hospital, in Brooklyn, NY). Further IRB approval at The Mayo Clinic in Rochester, MN is pending for Chronic Kidney Disease (CKD) III & IV patients.

The Company's novel probiotic dietary supplement product, Kibow® Biotics, utilizes a patented and proprietary bowel-based uremic toxin reduction technology for use in clinical applications towards maintaining a healthy kidney function. Kibow® Biotics has three probiotic microbial strains that are Generally Recognized As Safe (GRAS) by the U.S. FDA. This status essentially means that Kibow® Biotics is generally known, among skilled scientific and medical experts, as having been adequately shown to be safe under the conditions of its intended use.

Dr. Ranganathan states, "By developing an affordable, readily available and easy-to-administer dietary supplement, Kibow offers hope to all those who suffer from kidney problems in the USA and other countries, while in accordance with their respective governmental regulatory/registration authorities."

About Kibow Biotech:

Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product is called "Kibow® Biotics," an orally consumable, enteric-coated capsule formulation that is composed of food-grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug, dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.

About Chronic Kidney Disease (CKD)According to the National Kidney Foundation, more than 26 million Americans - one in nine adults - have kidney disease and most don't know it. Since kidney disease is often silent without any symptoms, it can go undiagnosed, especially in those who are not aware of the major risk factors. Anyone with high blood pressure, diabetes or a family history of these conditions or kidney disease is at risk and should get his or her kidneys checked. Kidney disease can be found and treated early to prevent more serious kidney disease and other complications.

Forward-looking statements:

Kibow® Biotics or any other dietary supplements are not intended to diagnose, treat, cure or prevent any disease as per the U.S. FDA. Kibow's website contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to: the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietary rights by the Company and its products; the establishment and maintenance of strategic collaborative and commercial relationships. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information:Natarajan Ranganathan, Ph.D.CEO and Senior VP (R&D)Tel: (610) 353-5130Toll Free: 1-888-271-2560info@kibowbiotech.com Website: http://www.kibow.com Facebook: http://www.facebook.com/kibowbiotech YouTube: http://www.youtube.com/kibowbiotech This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.
'/>"/>

SOURCE Kibow Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants
2. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
3. Thomson Reuters Launches Academic Reputation Survey as Part of Global Institutional Profiles Project
4. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
5. Schulman Associates IRB Establishes an Institutional Review Board in Canada
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
9. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
10. AEterna Zentaris Receives US$10 Million from Institutional Investors
11. NFGC Conducts Multi-Institutional Research Project in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 2016 , ... The American Academy of Thermology (AAT) has announced ... AAT Member Certification Qualification Course for Technicians via a two part webinar on July ... a detailed review of hardware, software, and camera setup/operations, aligns with the in-person member ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove announced today ... National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work ... throughout the drug regulatory review process. , “Adding Diane Dorman is just the ...
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of ... in Life-Changing Camp Experiences ... affect the lives of children born with rare diseases, as well ... ) is announcing a new initiative designed to positively affect the ... future of rare disease care. --> To mark the ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
Breaking Biology News(10 mins):